Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q1 2026 results will be published on April 23, 2026. About Sanofi Sanofi is an R&D driven, A ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved indication for ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved indication for ...

Core Insights - Kali Therapeutics has signed a licensing agreement with Sanofi to develop an experimental treatment for autoimmune diseases, specifically KT501 [1][2] Group 1: Licensing Agreement Details - Sanofi will acquire global rights to KT501, a tri-specific antibody developed using Kali Therapeutics' proprietary platform [2] - Kali Therapeutics will receive $180 million in upfront and near-term payments, with potential for up to $1.05 billion in development and commercial milestone payments [2] - The agreement includes tiered royalties on product sales, ranging from high-single digits to double digits if the drug is approved [2] Group 2: Drug Development and Testing - KT501 is currently undergoing early-stage testing in rheumatoid arthritis patients to evaluate its safety and tolerability [3] - Preclinical studies in non-human primates indicated that KT501 significantly reduced B cells while minimizing adverse immune reactions associated with similar treatments [3][4] - The drug is designed to target and modulate immune cells involved in autoimmune disorders, including lupus and rheumatoid arthritis [4] Group 3: Sanofi's Existing Portfolio - Sanofi markets Kevzara, an approved rheumatoid arthritis treatment developed in collaboration with Regeneron Pharmaceuticals, and is also advancing new anti-inflammatory candidates [4]

证券研究报告 多发性硬化症全球累及患者群体庞大， BTK抑制剂有望成为新型治疗方案 医药行业深度报告 证券分析师 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 风险提示：行业政策变动风险；研发进展不及预期风险；竞争加剧风险；产品上市后商业化表现不及预期等。 1 多发性硬化症全球累及患者群体庞大，欧美相对高发。多发性硬化症（multiple sclerosis，MS）是免疫介导的中枢神经系统炎性脱髓鞘疾病，其起病方式以 急性和亚急性多见，最常累及脑室周围白质、脊髓、脑干、小脑与视神经。MS的症状体征异质性较强，常伴有视力丧失，运动和感觉障碍以及认知障碍。MS临 床病程可能表现为复发缓解病程、进行性疾病病程或其组合。MS发病年龄多在20～40岁之间，高峰年龄在30岁左右，男女性别之比约为1∶1.5。全球范围内超 200万MS患者，是除脑 ...

Sanofi launches innovation and operation centre in China | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of French drugmaker Sanofi is seen in Paris, France, January 9, 2026. REUTERS/Gonzalo Fuentes/File Photo Purchase Licensing Rights, opens new tab BEIJING, March 20 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tablaunched an innovation and operation centre in the southwestern Chinese city of Chengdu on Thurs ...

点击小程序查看报告原文 Abstract 摘要 通过"跨国公司成长启示录"，我们希望总结跨国龙头的成功经验，为中国企业的全球化发展提供参考。第一篇主要探讨跨国公司的发展历程及其在全球经 济中的重要性， 本篇报告重点 关注 美国、欧洲、日本三个区域跨国公司的发展情况， 将从企业为何出海、数说跨国公司、典型行业（选取美国科技、欧 洲医药、日本汽车）分别展开。 基于对美欧日跨国公司的比较，我们发现虽然三大经济体企业出海的时代背景各异，但是 底层逻辑上呈现高度一致性，即突破增长天花板、规避贸易壁 垒、全球范围成本套利。 与此同时，不同经济体依托各自资源禀赋、产业根基、制度框架，全球化历程走出不同的发展路径。我们总结如下： 美国：聚焦高附加值，技术引领全球。 1）从出海必要性而言，美国反垄断监管限制大企业的国内发展空间，是企业海外扩张的重要原因。另外，追求生 产要素最优配置是跨国公司构筑全球竞争力的基础逻辑，近年来提高供应链安全成为海外投资布局的重要考量。2）美国凭借全球领先的研发创新体系、 完善的知识产权保护制度、成熟的科技成果转化机制，在高附加值领域构筑技术护城河，科技行业最为典型。我们认为 ①建立领先优势并掌控全 ...

At ELAM1, we empower financial professionals and investors with the scientific and clinical expertise required to navigate the complexities of the healthcare sector. By bridging the gap between cutting-edge science and financial strategy, we help our clients uncover hidden value, assess risks with greater accuracy, and make more informed investment decisions in life sciences. Feel free to reach us or to visit our website for more informations about us and our services.Analyst’s Disclosure: I/we have no stoc ...

Investment Rating - The report indicates a positive outlook for the neurodegenerative disease drug market, with expectations for continued expansion driven by various factors such as aging population and innovative therapies [4][16]. Core Insights - Neurodegenerative diseases are characterized by progressive loss of neurons, significantly impacting memory, cognition, behavior, and motor control [4]. - The global and Chinese neurodegenerative disease drug markets are projected to grow, with the global market expected to reach $99.9 billion by 2033, and the Chinese market anticipated to grow to $6.5 billion [16]. - Companies are increasingly utilizing mergers and acquisitions to enhance their competitive edge in Alzheimer's treatment, focusing on diverse mechanisms and technologies [4][27]. Summary by Sections Industry Overview - The neurodegenerative disease market is expanding due to factors like increased patient numbers from aging, breakthroughs in targeted and gene therapies, and advancements in early screening technologies [4][16]. - The industry is characterized by a complex drug development process, with high barriers due to the intricate pathology of these diseases [9][10]. Alzheimer's Disease Market - The number of Alzheimer's patients globally is expected to rise from 38.4 million in 2024 to 43.5 million by 2033, with a compound annual growth rate (CAGR) of 1.5% [24]. - The report highlights a shift towards multi-target interventions in drug development, with a focus on both symptomatic relief and disease modification [29][32]. - Mergers and acquisitions in the Alzheimer's sector are frequent, with companies acquiring technologies to diversify treatment options [26][27]. Parkinson's Disease Market - The number of Parkinson's patients in China is projected to increase from 3.4 million in 2024 to 6.2 million by 2033, reflecting a CAGR of 6.0% [38]. - The treatment landscape for Parkinson's includes various stages and methods, from early-stage medication to advanced surgical interventions [36][38]. - Research continues to focus on optimizing traditional drug targets while exploring new avenues for treatment [5]. Multiple Sclerosis Market - The treatment options for multiple sclerosis (MS) are diverse, with various mechanisms of action, but there remains a significant unmet clinical need due to product shortages [6]. - The report emphasizes the need for innovative strategies to address the different subtypes of MS and their respective treatment challenges [6]. Market Dynamics - The report outlines a positive trend in the neurodegenerative disease drug market, driven by demographic changes and technological advancements in drug development [16][18]. - The industry is witnessing a shift towards collaborative efforts and international partnerships to enhance research capabilities and market presence [9][10].